Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980023/S146

Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

Biotronik, Inc. · Decision date Sep 17, 2026

MEDTECHLEDGER EXPLANATIONP980023/S146

What did the FDA approve?

The FDA lists P980023/S146 as an approval dated 2026-09-17 for Biotronik, Inc., covering Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX and related Riva models, product code LWS. The database labels the supplement type as Real-Time Process and the reason as a change to design, components or specifications/material. The identifier places it as supplement S146 to PMA P980023, so it modifies that existing approval rather than constituting a separate original approval.

The reported statement is approval for updated programmer software PSW 2601.U and NEO 2601.U. The record does not specify which components changed, what the update alters technically, or how the software relates to the listed defibrillator models; that information is absent. This field reports a regulatory action and does not establish safety or clinical effectiveness.

FDA approval order statement

approval for updated programmer software PSW 2601.U and NEO 2601.U
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 17, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980023/S146
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Sep 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980023 · Original PMA

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  2. P980023/S146 received

    Application receipt date recorded by FDA.

  3. P980023/S150 · Related supplement

    Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6

  4. P980023/S146 · FDA decision

    Real-Time Process

  5. P980023/S140 · Related supplement

    Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

  6. P980023/S151 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  7. P980023/S149 · Related supplement

    Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D

  8. P980023/S152 · Related supplement

    Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-

  9. P980023/S153 · Related supplement

    Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri

Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980023

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records